Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload

Journal of Magnetic Resonance Imaging

Volumn 23, Issue 5, 2006, Pages 662-668

  Pepe, Alessia ^a,b   Positano, Vincenzo ^a   Santarelli, Maria Filomena ^a   Sorrentino, Fortunato ^b   Cracolici, Eliana ^b   De Marchi, Daniele ^a   Maggio, Aurelio ^c   Midiri, Massimo ^b   Landini, Luigi ^d   Lombardi, Massimo ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiomyopathy; Iron overload; Magnetic resonance imaging; Relaxation time (T2*); Thalassemia

Indexed keywords

FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CARDIOMYOPATHY; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE; HEART VENTRICLE SEPTUM; HUMAN; IMAGE PROCESSING; IRON CHELATION; IRON OVERLOAD; IRON URINE LEVEL; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HEART VENTRICLES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS;

EID: 33646175588     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20566     Document Type: Article

References (21)

1. Weatherall DJ, Clegg JB. Thalassemia-a global public health problem. Nat Med 1996;2:847-849.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
3. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-117.
4. Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 1993;103:1276-1278.
5. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferioxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229-1236.
6. Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patient with transfusion anemia and secondary myocardial iron deposition. Am J Med 1978; 64:547-455.
7. Nienhuis AW, Griffith P, Strawczynsky H, et al. Evaluation of cardiac function in patients with thalassaemia major. Ann NY Acad Sci 1980;344:384-396.
8. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation study of iron overload in beta-thalassemia major. MAGMA 1998;6:7-12.
9. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2 star (T2*) magnetic resonance for early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
10. Anderson LJ, Wonke B, Prescott E, Holden S, Walker M, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferioxamine on myocardial iron concentration and ventricular function in beta-thalassemia. Lancet 2002;360:516-520.
11. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial overload. J Magn Reson Imaging 2003;18: 33-39.
12. Westwood M, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003; 18:616-620.
13. Anderson LJ, Westwood M, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
14. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987;10:1239-1243.
15. Olson LJ, Edwards WD. Endomyocardial biopsy in hemochromatosis: clinical-pathologic correlates in six cases. J Am Coll Cardiol 1989;13:116-120.
16. Bellenger NG, Pennell DJ. Assessment of ventricular function. In: Manning WJ, Pennell DJ. editors. Cardiovascular magnetic resonance. New York: Churchill Livingstone; 2002. p 99-111.
17. Brittenaham GM, Griffith PM, Nienhuis AW. et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
18. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-578.
19. Olvieri NF, Brittenaham GM. Iron chelating therapy and the treatment of thalassemia. Blood 1997;89:736-761.
20. Sijbers J, den Dekker AJ, Scheunders P, Van Dick D. Maximum likelihood estimation of Rician distribution parameters. IEEE Trans Med Imaging 1998;17:357-361.
21. Reeder SB, Faranesh AZ, Boxerman JL, McVeigh ER. In vivo measurement of T2* and field inhomogeneity maps in the human heart at 1.5 T. Magn Reson Med 1998;39:988-998.